Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT02242357
NCT02242357CompletedNot Applicable

Post-Marketing Surveillance Study Micardis® Plus

Boehringer Ingelheim0 sites14,553 target enrollmentStarted: January 2003Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
14,553
Primary Endpoint
Change in morning blood pressure (office and self-measured)
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Study to evaluate efficacy and tolerability of Micardis®/Micardis® Plus under usual daily-practice prescribing conditions in hypertensive patients

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Males and females for whom a medical antihypertensive therapy is indicated
  • •Age >= 18 years

Exclusion Criteria

  • •Age < 18 years

Arms & Interventions

Patients with hypertension

Intervention: Micardis® (Drug)

Patients with hypertension

Intervention: Micardis® Plus (Drug)

Outcomes

Primary Outcomes

Change in morning blood pressure (office and self-measured)

Time Frame: up to 6 weeks

Secondary Outcomes

  • Assessment of tolerability by investigator on 5-point scale(at week 6)
  • Change in rate of morning complaints(up to 6 weeks)
  • Assessment of efficacy by investigator on a 5-point scale(at week 6)
  • Number of patients with adverse drug reactions(up to 6 weeks)
  • Change in heart rate(up to 6 weeks)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials

Completed
Not Applicable
Post-Marketing Surveillance Study of Micardis® Plus in Patients With HypertensionHypertension
NCT02238275Boehringer Ingelheim8,135
Completed
Not Applicable
Safety, Tolerability and Efficacy of Micardis® in Patients With Essential HypertensionHypertension
NCT02176850Boehringer Ingelheim19,870
Completed
Not Applicable
Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)Hypertension
NCT02262637Boehringer Ingelheim4,814
Completed
Not Applicable
Micardis®. Observational Study in Patients With Essential HypertensionHypertension
NCT02200094Boehringer Ingelheim4,532
Completed
Not Applicable
Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With HypertensionHypertension
NCT02242838Boehringer Ingelheim6,336